Carboplatin and etoposide as outpatient treatment of advanced non-small-cell lung cancer.
Twenty-four outpatients with locally advanced (inoperable or unsuitable for radical radiotherapy) or metastatic non-small-cell lung cancer were treated with carboplatin (300 mg/m2 day 1)+etoposide (120 mg/2 day 1-3), every 3 weeks. Two patients died of disease progression before completing at least 2 cycles of chemotherapy. Four patients (16.7%) obtained a partial response, 10 had disease stabilization (41.7%) and 8 progressed (33.3%). Median overall survival was 8 months (range 1-22). Toxicity was moderate, with no nephro-, neuro- or ototoxicity.